Cargando…

Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives

The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body...

Descripción completa

Detalles Bibliográficos
Autores principales: Barone, Ines, Caruso, Amanda, Gelsomino, Luca, Giordano, Cinzia, Bonofiglio, Daniela, Catalano, Stefania, Andò, Sebastiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285685/
https://www.ncbi.nlm.nih.gov/pubmed/34559450
http://dx.doi.org/10.1111/obr.13358
_version_ 1784747836295872512
author Barone, Ines
Caruso, Amanda
Gelsomino, Luca
Giordano, Cinzia
Bonofiglio, Daniela
Catalano, Stefania
Andò, Sebastiano
author_facet Barone, Ines
Caruso, Amanda
Gelsomino, Luca
Giordano, Cinzia
Bonofiglio, Daniela
Catalano, Stefania
Andò, Sebastiano
author_sort Barone, Ines
collection PubMed
description The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The mechanisms behind the interplay between obesity and endocrine therapy resistance are likely to be multifactorial. Therefore, what have we actually learned during these years and which are the main challenges in the field? In this review, we will critically discuss the epidemiological evidence linking obesity to endocrine therapeutic responses and we will outline the molecular players involved in this harmful connection. Given the escalating global epidemic of obesity, advances in understanding this critical node will offer new precision medicine‐based therapeutic interventions and more appropriate dosing schedule for treating patients affected by obesity and with breast tumors resistant to endocrine therapies. [Image: see text]
format Online
Article
Text
id pubmed-9285685
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-92856852022-07-18 Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives Barone, Ines Caruso, Amanda Gelsomino, Luca Giordano, Cinzia Bonofiglio, Daniela Catalano, Stefania Andò, Sebastiano Obes Rev Obesity Comorbidity/Etiology and Pathophysiology The incidence of obesity, a recognized risk factor for various metabolic and chronic diseases, including numerous types of cancers, has risen dramatically over the recent decades worldwide. To date, convincing research in this area has painted a complex picture about the adverse impact of high body adiposity on breast cancer onset and progression. However, an emerging but overlooked issue of clinical significance is the limited efficacy of the conventional endocrine therapies with selective estrogen receptor modulators (SERMs) or degraders (SERDs) and aromatase inhibitors (AIs) in patients affected by breast cancer and obesity. The mechanisms behind the interplay between obesity and endocrine therapy resistance are likely to be multifactorial. Therefore, what have we actually learned during these years and which are the main challenges in the field? In this review, we will critically discuss the epidemiological evidence linking obesity to endocrine therapeutic responses and we will outline the molecular players involved in this harmful connection. Given the escalating global epidemic of obesity, advances in understanding this critical node will offer new precision medicine‐based therapeutic interventions and more appropriate dosing schedule for treating patients affected by obesity and with breast tumors resistant to endocrine therapies. [Image: see text] John Wiley and Sons Inc. 2021-09-24 2022-02 /pmc/articles/PMC9285685/ /pubmed/34559450 http://dx.doi.org/10.1111/obr.13358 Text en © 2021 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Obesity Comorbidity/Etiology and Pathophysiology
Barone, Ines
Caruso, Amanda
Gelsomino, Luca
Giordano, Cinzia
Bonofiglio, Daniela
Catalano, Stefania
Andò, Sebastiano
Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title_full Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title_fullStr Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title_full_unstemmed Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title_short Obesity and endocrine therapy resistance in breast cancer: Mechanistic insights and perspectives
title_sort obesity and endocrine therapy resistance in breast cancer: mechanistic insights and perspectives
topic Obesity Comorbidity/Etiology and Pathophysiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285685/
https://www.ncbi.nlm.nih.gov/pubmed/34559450
http://dx.doi.org/10.1111/obr.13358
work_keys_str_mv AT baroneines obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT carusoamanda obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT gelsominoluca obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT giordanocinzia obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT bonofigliodaniela obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT catalanostefania obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives
AT andosebastiano obesityandendocrinetherapyresistanceinbreastcancermechanisticinsightsandperspectives